Clinical Trial Update: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 study of Orforglipron (LY3502970) for obesity/overweight with Type 2 diabetes is currently active but not recruiting, sponsored by Eli Lilly and Company…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: ACTIVE_NOT_RECRUITING